Jefferies Maintains Buy on Auxilium Pharma (AUXL)

Jefferies is out with its report on Auxilium Pharma AUXL, maintaining Buy. In a note to clients, Jefferies writes, "Today, AUXL presented an update on Xiaflex sales metrics through March to investors. We continue to believe that Xiaflex adoption in Dupuytren's is gated by reimbursement concerns rather than clinical concerns, and anticipate steady Xiaflex sales growth in 2011 with sales acceleration in 2012." Jefferies has a $39 PT on AUXL. Shares of AUXL closed Tuesday at $21.44, up 1.71% from Monday's close.